2006CCO伊莫單抗治療淋巴瘤診療指南
《2006CCO伊莫單抗治療淋巴瘤診療指南》內(nèi)容簡介：
This systematic review is a convenient and up-to-date source of the best availableevidence on ibritumomab tiuxetan in lymphoma. The body of evidence is comprised of dataprimarily from non-randomized controlled trial data or data available only in abstract form. Thatevidence forms the basis of a clinical practice guideline developed by the Hematology DSG.The systematic review and companion practice guideline are intended to promote evidence-based practice in Ontario, Canada. The PEBC is editorially independent of CCO and the OntarioMinistry of Health and Long-Term Care.
《2006CCO伊莫單抗治療淋巴瘤診療指南》內(nèi)容預(yù)覽：
Entries to MEDLINE （Ovid） （1966 through May 2004）， MEDLINE Daily Update （Ovid）（May 19, 2004）， MEDLINE? In-Process & Other Non-Indexed Citations （Ovid） （May 19, 2004），HealthStar （Ovid） （1975 through April 2004）， CINAHL （Ovid） （1982 through May 2004）， and TheCochrane Library （Internet） （2004, Issue 2） databases were searched. The search strategy forMEDLINE is shown in Appendix I; searches in other Ovid databases were similar. Studies werelimited to humans but not restricted for language of publication or for publication type or studydesign.
In addition, conference proceedings of the annual meetings of the American Society ofClinical Oncology （ASCO） （1995-2004） and the American Society of Hematology （ASH） （1996-2004） were searched for abstracts of relevant trials. The Canadian Medical AssociationInfobase （http://mdm.ca/cpgsnew/cpgs/index.asp）， the National Guidelines Clearinghouse（http://www.guideline.gov/index.asp）， and the National Institute for Clinical Excellence（http://www.nice.org.uk/） were also searched for existing evidence-based practice guidelines.
Personal files were also searched.
Relevant articles and abstracts were selected unblinded and independently by tworeviewers. Reviewers scored each item as “yes” （meets inclusion criteria）， “no” （if does notmeet inclusion criteria）， or “maybe” （if uncertainty regarding inclusion exists）。 If both reviewersagreed that the item met the inclusion criteria, the complete document was retrieved for further**ysis. When disagreements occurred, both reviewers reassessed together to achieveconsensus. When a score of “maybe” was given by both reviewers or if disagreementpersisted, the full document was retrieved and the inclusion criteria reapplied. Reasons forexcluding retrieved articles were documented. Agreement between the two reviewers wasassessed statistically by using the kappa statistic.
點擊下載***：《2006CCO伊莫單抗治療淋巴瘤診療指南》
本站所注明來源為"愛愛醫(yī)"的文章，版權(quán)歸作者與本站共同所有，非經(jīng)授權(quán)不得轉(zhuǎn)載。
本站所有轉(zhuǎn)載文章系出于傳遞更多信息之目的，且明確注明來源和作者，不希望被轉(zhuǎn)載的媒體或個人可與我們
聯(lián)系zlzs@120.net，我們將立即進行刪除處理
熱點圖文
-
2013我國胰腺囊性腫瘤共識意見草案
本共識意見（草案）依據(jù)我國胰腺囊性腫瘤的最近研究，并參考國際相關(guān)指南和研究...[詳細]
-
2013NCCN結(jié)直腸癌指南
在美國，結(jié)直腸癌發(fā)病率占所有癌癥的第四位，而死亡率為第二位。2012年估計...[詳細]
